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1. Perioperative statins reduce perioperative myocardial infarctions, atrial fibrilla-
tion, and length of stay.
2. Statin use does not increase the risk of intracranial hemorrhage.
3. New oral anticoagulant agents are superior to warfarin in preventing stroke in
patients with atrial fibrillation, and may have a better safety profile.
4. In patients with an acute upper gastrointestinal (GI) bleed, the threshold for red
blood cell transfusion should likely be a hemoglobin less than 7 g/dL.
5. In patients who have an acute GI bleed while on warfarin, restarting the
warfarin after a week may lead to fewer thromboses and lower mortality
without increasing the bleeding risk.
6. Patients admitted to the hospital with an exacerbation of chronic obstructive
pulmonary disease should receive antibiotics in addition to bronchodilators
and steroids.
7. Patients with low English proficiency should receive professional interpreter
services on hospital admission.
8. Unnecessary proton pump inhibitors should be discontinued and their use
should be limited to patients who cannot tolerate other acid suppression
therapies.
9. Treatment with a 7-day course of oral ciprofloxacin should be considered for
patients with acute, uncomplicated pyelonephritis.
10. Dogs may be trained to accurately detect Clostridium difficile infection by
sense of smell on hospital wards.What effects do perioperative statins have on myocardial infarction, atrial
fibrillation, death, and length of stay?
Chopra V, Wesorick DH, Sussman JB, et al. Effect of perioperative statins on
death, myocardial infarction, atrial fibrillation, and length of stay. Arch Surg
2012;147(2):181–9.BACKGROUND/PURPOSE
Despite advances in anesthetic and operative techniques, cardiac complications of
surgery are common. Although tools exist to identify patients at high risk for perioper-
ative complications, there are few proven medical interventions to reduce the risk. The
purpose of the analysis was to determine the effects of statins, administered in the
perioperative period, on the risk of myocardial infarction, atrial fibrillation, death,
and length of stay (LOS).STUDY DESIGN
The investigators performed a systematic review andmeta-analysis of 15 randomized,
controlled studies. The primary outcomes were perioperative myocardial infarction,
perioperative atrial fibrillation, perioperative death, and LOS. The 15 studies examined
were determined to be of high quality.
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In the pooled analysis, 2292 statin naive patients who were randomized to receive
perioperative statins versus placebo (or low-dose statins) were examined. The dura-
tion of statin treatment varied across studies (range 7–60 days). In the pooled analysis,
statin treatment was associated with a significant reduction in the risk of perioperative
myocardial infarction (4.5% vs 8.9%; relative risk [RR], 0.53; 95% confidence interval
[CI], 0.38–0.74) and perioperative atrial fibrillation (19.9% vs 36.3%; RR, 0.56; 95% CI,
0.45–0.69). In addition, statin treatment was associated with a 2.2% incidence of
death compared with 3.7% among controls, but the difference was not significant
(RR, 0.6; 95% CI, 0.34–1.14). There was no heterogeneity among studies for these
three outcomes. Treatment with statins was also associated with a significant reduc-
tion in LOS (0.32 days) but there was a high degree of heterogeneity among studies.
The investigators did not find evidence that any particular duration of statin treatment
was more effective than another, but in most studies patients were treated with statins
at least 7 days before surgery.
SUMMARY
Overall, this systematic review and meta-analysis of 15 high-quality randomized
controlled trials offers strong evidence that perioperative statins reduce the risk of
perioperative myocardial infarction and atrial fibrillation, and may also reduce the
risk of perioperative death.Does statin use increase patients’ risk for intracranial hemorrhage?
McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemor-
rhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012;43:
2149–56.BACKGROUND/PURPOSE
Several stroke prevention trials have shown that statins significantly reduce the risk of
ischemic stroke. One of these, The Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) study, found that atorvastatin reduced overall stroke,
but not fatal stroke. A post hoc analysis found that atorvastatin was associated with
significantly increased risk of hemorrhagic stroke.
STUDY DESIGN
To determine whether statin therapy increases the risk of intracranial hemorrhage, the
investigators performed a systematic review and meta-analysis of 31 randomized
controlled trials of statin therapy. In the pooled analysis, 91,588 patients treated
with statins and 91,215 control patients given placebo, low-dose statins, or usual
care were examined. All studies included in the analysis were randomized controlled
trials with blinded outcome assessment.
RESULTS
In the pooled analysis, intracranial hemorrhage occurred in 358 subjects (0.39%)
treated with statins versus 318 (0.35%) in the control group. Statin therapy was not
Southern et ale296associated with significantly increased risk of intracranial hemorrhage (odds ratio
[OR], 1.08; 95% CI, 0.88–1.32). In addition, the investigators found no association be-
tween the low-density lipoprotein (LDL) reduction or LDL level achieved and the risk of
intracranial hemorrhage.
This analysis could not rule out a small increased risk for intracranial hemorrhage,
because an excess of 25 intracranial hemorrhages were noted. To address the possi-
bility of small harm, the investigators compared the magnitude of the possible harm
with the magnitude of the benefits of statin therapy. In the same pooled analysis statin
therapy prevented 540 strokes and 638 deaths. Thus the benefits of statin therapy far
outweighed the possible harm.
SUMMARY
Overall, statin therapywas not associatedwith significantly increased risk of intracranial
hemorrhage. Although a small degree of harm could not be ruled out, the magnitude of
the benefits (reduced overall strokes and mortality) far outweighed the possible harm.Are new oral anticoagulant agents effective and safe for preventing stroke in
patients with atrial fibrillation?
Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of
new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin
in patients with atrial fibrillation. Am J Cardiol 2012;110:453–60.BACKGROUND/PURPOSE
Warfarin has been the standard therapy for preventing stroke in patients with atrial
fibrillation for many years. Warfarin therapy is limited by the narrow therapeutic win-
dow of adequate anticoagulation without bleeding and by the variable dosing among
patients, which requires close monitoring. New oral anticoagulant (NOA) agents
include direct thrombin inhibitors (eg, dabigatran) and factor Xa inhibitors (eg, rivarox-
aban and apixaban). New oral anticoagulant agents offer predictable dosing for most
patients, and no need for continuous monitoring. Several randomized controlled trials
have shown that NOAs are efficacious in preventing strokes in patients with atrial fibril-
lation, but none has compared the efficacy among NOAs or examined safety in pooled
analyses.
STUDY DESIGN
The investigators performed a systematic review and meta-analysis of 3 randomized
controlled trials of NOAs versus warfarin in patients with atrial fibrillation. The 3 trials
included 1 each that examined the efficacy of dabigatran, rivaroxaban, and apixaban.
In pooled analysis, 44,563 patients randomized to receive an NOA or warfarin were
examined. Treatment outcomes included all-cause stroke and systemic embolism,
and hemorrhagic stroke. Safety outcomes included major bleeding, intracranial
bleeding, and gastrointestinal (GI) bleeding.
RESULTS
In the pooled analysis, treatment with an NOA was associated with significantly
decreased risk of all-cause stroke and systemic embolism (RR, 0.78; 95% CI,
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with warfarin. In the safety analysis, treatment with an NOA was associated with
a significant reduction in intracranial bleeding (RR, 0.49; 95%CI, 0.36–0.66) compared
with warfarin. Treatment with an NOA was also associated with a nonsignificant
decrease inmajor bleeding (RR, 0.88; 95%CI, 0.71–1.09) and a nonsignificant increase
in GI bleeding (RR, 1.25; 95% CI, 0.91–1.72) compared with warfarin.
It is worth noting that the mean time in the therapeutic range for patients treated with
warfarin ranged from 55% to 64% among the three studies. It is likely that warfarin
would be more efficacious and safe if a higher time in the therapeutic range could
be achieved, but the time in range seen in the studies is approximately what is seen
in clinical practice.
SUMMARY
Taken together the three trials examined provide strong evidence that NOAs are supe-
rior to warfarin in preventing stroke and hemorrhagic stroke, and likely also have a bet-
ter safety profile.At what hemoglobin level should be transfused in the setting of an acute up-
per GI bleed?
Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper
gastrointestinal bleeding. N Engl J Med 2013;368:11–21.BACKGROUND/PURPOSE
Patients with an acute upper GI bleed (UGIB) often require red blood cell transfusion.
The optimal hemoglobin level at which to transfuse is unclear.
STUDY DESIGN
Investigators enrolled 921 patients who presented to a single hospital in Spain be-
tween 2003 and 2009 with an acute UGIB (all presented with hematemesis or melena).
Patients were randomized to either a restrictive transfusion strategy (transfuse for
hemoglobin less than 7 g/dL) or a liberal strategy (transfuse for hemoglobin less
than 9 g/dL). All patients received 1 unit of packed red blood cells before enrollment
and all underwent endoscopy within 6 hours of admission.
RESULTS
The 2 most common diagnoses were peptic ulcer disease (49%) and variceal bleeding
(21%). Patients in the restrictive strategy were significantly less likely to be transfused
(49% vs 86%; P<.001). Patients in the restrictive strategy group also had less rebleed-
ing (10% vs 16%; P 5 .01) and a lower mortality at 45 days (5% vs 9%; P 5 .02).
Although patients in the restrictive strategy group had a lower hemoglobin at
discharge, this difference disappeared by 45 days.
SUMMARY
There are a few minor methodological issues with this study that could limit the ability
to generalize from it: all the patients received 1 unit before enrollment, it was not a
Southern et ale298blinded study, and all patients had endoscopy within 6 hours. However, given the
mounting evidence from other clinical scenarios supporting a restrictive transfusion
strategy, this well-done study seems valid and likely should change clinical practice.
In general, in the setting of an acute UGIB, clinicians should only transfuse for a hemo-
globin less than 7 g/dL or if indicated clinically.If a patient on warfarin has an acute GI bleed, when is it safe and appropriate
to restart the warfarin?
Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hem-
orrhage, and death after warfarin therapy interruption for gastrointestinal
tract bleeding. Arch Intern Med 2012;172(19):1484–91.BACKGROUND/PURPOSE
Patients on warfarin (for any indication) are at increased risk for GI bleeding. If they
have a bleeding episode, there is little evidence describing the optimal time
to restart the warfarin, balancing the risk of recurrent bleeding with the risk of
thrombosis.
STUDY DESIGN
Researchers performed a retrospective cohort study to determine the incidence of
thrombosis, recurrent GI bleed, and death in patients who had a GI bleed and in
whom the warfarin was stopped. Using a large Kaiser database, 442 patients who
had a GI bleed on warfarin were identified; the most common indications for warfarin
were atrial fibrillation (50%) and venous thromboembolism (25%). Approximately one-
third of the patients required intensive care unit (ICU) care for their GI bleed, whereas
25% were discharged from the emergency department. Of these 442 patients, 260
resumedwarfarin (59%); the median time to resumption was 4 days. Younger patients,
those with mechanical valves, and those who had a lower GI bleed were more likely to
resume warfarin. The investigators performed a complex propensity analysis to try to
control for confounders.
RESULTS
The risk of thrombosis was significantly lower in those patients who resumed warfarin
compared with those who did not (0.4% vs 5.5%; hazard ratio, 0.05; P<.001). There
was not an increased risk for recurrent bleeding within 90 days in patients who
restarted the warfarin (hazard ratio, 1.32; P5 .9). Restarting anticoagulation was asso-
ciated with a significant decrease in 90-day mortality (hazard ratio, 0.31; P 5 .001).
When examining by time to resumption of warfarin, waiting 7 days may have yielded
the best outcomes.
SUMMARY
Clinicians frequently face the complex decision of when to restart the warfarin in a pa-
tient who has recently had a GI bleed. Although this study is not perfect, it suggests
that restarting warfarin in this setting may lead to fewer thromboses and maybe lower
mortality without increasing the risk for recurrent bleeding. Although the data are not
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case basis, clinicians should strongly consider restarting. If the decision is made to
restart, waiting at least a week is most appropriate.In patients hospitalizedwith an exacerbation of chronic obstructive pulmonary
disease, is there a benefit to prescribing antibiotics in addition to bronchodila-
tors and steroids?
Stefan MS, Rothberg MB, Shieh MS, et al. Association between antibiotic treat-
ment and outcomes in patients hospitalized with acute exacerbation of COPD
treated with systemic steroids. Chest 2013;143(1):82–90.BACKGROUND
There is substantial evidence supporting the use of bronchodilators and steroids in
patients hospitalized with a chronic obstructive pulmonary disease (COPD) exacerba-
tion. Although there is reasonable evidence supporting the use of antibiotics in these
patients, most of the studies excluded patients who receive steroids. It is not clear
whether antibiotics have an added benefit in patients given bronchodilators and ste-
roids for their COPD exacerbations.STUDY DESIGN
The investigators conducted a retrospective cohort study using a large database
of more than 53,000 patients more than 40 years of age who were admitted to an
acute care hospital with an exacerbation of COPD (determined by International
Classification of Diseases, Ninth Revision coding). Patients admitted to the ICU
were excluded and all patients received systemic steroids. Patients given an-
tibiotics in the first 48 hours were compared with those not given antibiotics;
multivariable analysis and propensity scoring were performed to control for
confounders.RESULTS
More than 86% of patients were given antibiotics in the first 48 hours and the most
common antibiotic prescribed was a quinolone. Patients prescribed antibiotics had
a significantly lower in-hospital mortality (adjusted OR, 0.53; 95% CI, 0.40–0.71). Pa-
tients prescribed antibiotics also had lower 30-day readmission rates for COPD
(adjusted OR, 0.88; 95% CI, 0.79–0.97). There was no increase in rates of Clostridium
difficile infection and no antibiotic was superior.SUMMARY
This well-done retrospective cohort study adds to a large body of evidence supporting
the use of antibiotics in the treatment of acute exacerbations of COPD requiring hos-
pitalization. Absent any contraindications, patients admitted to the hospital with a
COPD exacerbation should receive antibiotics in addition to bronchodilators and
steroids.
When should non–English speaking patients receive professional interpreter
services?
Lindholm M, Hargraves JL, Ferguson WJ, et al. Professional language interpre-
tation and inpatient length of stay and readmission rates. J Gen Intern Med
2012;27(10):1294–99.
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People with limited English proficiency often have difficulty explaining their symptoms
during the hospitalizations and understanding their care plan afterward. Low English
proficiency is associated with longer LOS, increased risk for serious adverse events
after discharge, and higher rehospitalization rates.STUDY DESIGN
To determine whether timing of professional interpreter services was associated with
differences in hospital LOS or 30-day rehospitalization rates, the investigators per-
formed a retrospective, observational study using administrative and clinical data
from 3071 adult patients who received professional interpretation services at a large,
tertiary care teaching hospital. Professional interpreters at this hospital were screened
for bilingual oral and written language proficiency and had more than 90 hours of di-
dactic and practical training before providing services. Patients’ LOS and readmission
rates were compared with rates when they received interpreter services (none on
admission or discharge, on admission only, on discharge only, or on admission and
discharge). The analyses were adjusted for patient characteristics, disease severity,
and primary language.RESULTS
LOS at the study hospital ranged from 1 to 85 days, with 75% having LOS less than
6 days. Compared with patients who received interpreter services at both admission
and discharge, the LOS of patients who did not receive interpreter services at admis-
sion or discharge were 1.49 days longer (P<.01). Overall 30-day rehospitalization rate
was 17.9%. Rehospitalization rates were significantly higher for patients who did not
receive interpreter services on admission and/or discharge (24.3% vs 16.9% inter-
preter on admission only, 17.6% interpreter on discharge only, 14.9% interpreter on
admission and discharge; P<.001).SUMMARY
The chief concern with this observational study is that it may not be possible to gener-
alize the findings to all hospitals, given how thoroughly professional interpreters at the
study hospital were vetted and trained. However, the effect sizes reported in this
otherwise rigorous study were impressive. To the extent that services are available,
hospitalists should involve professional interpreters at the time of admission or at
admission and discharge.
Do proton pump inhibitors increase hospitalized patients’ risk for C. difficile–
associated diarrhea?
Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-associated diarrhea
and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol
2012;107(7):1001–10.
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C. difficile is the most common infectious cause of health care–associated diarrhea
in developed countries. Antibiotics remain the primary risk factor associated with
C. difficile–associated diarrhea (CDAD), but conflicting studies have reported a
possible link between proton pump inhibitor (PPI) use and CDAD.
STUDY DESIGN
The investigators conducted a meta-analysis of 23 articles (17 case-control and 6
cohort studies) identified through a PubMed search to evaluate the direction and
magnitude of association between PPI use and CDAD. The investigators converted
ORs reported in case-control studies to RRs to determine the pooled risk estimates.
RESULTS
The included studies involved a total of 288,620 patients. Overall, PPI exposure was
associated with a nearly 70% increased risk for CDAD (RR, 1.69; 95% CI, 1.40–
1.97). Systematic assessments of risk for bias found evidence for heterogeneity
among the studies but no evidence for publication bias. Sensitivity analyses using
random-effects models for all included studies as well as subgroups consisting of
only case-control or cohort studies produced similar results.
SUMMARY
Although limited by the absence of controlled trials in the literature, this rigorously con-
ducted meta-analysis contributes to a growing body of evidence that links PPI use to
C. difficile–associated infections. Unless patients have clear indications for acid sup-
pression, hospitalists should avoid prescribing PPIs and should discontinue their use
whenever possible.Is it safe to treat women with acute pyelonephritis for 7 days?
Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus
14 days in women with acute pyelonephritis: a randomised, open-label and
double-blind, placebo-controlled, non-inferiority trial. Lancet
2012;380(9840):484–90.BACKGROUND/PURPOSE
Acute pyelonephritis is a common infection among women of all ages. Prior studies
have shown that treating with either trimethoprim-sulfamethoxazole or a
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optimal duration of antibiotic therapy for this condition is unclear.STUDY DESIGN
The investigators conducted a multicenter, double-blind, randomized controlled non-
inferiority trial of 248 adult, nonpregnant Swedish women who were presumptively
diagnosed with acute pyelonephritis. Women were included if they were 18 years
old or older, had a fever greater than or equal to 38.0 C, and one of the following symp-
toms: flank pain, costovertebral angle tenderness, dysuria, urgency, or frequency.
They were excluded if they had an indwelling urinary catheter, intermittently catheter-
ized their bladder, used antibiotics within 72 hours of enrollment, or had any contrain-
dications to fluoroquinolone therapy. Randomized patients received ciprofloxacin
500 mg twice a day for either 7 or 14 days. Outcomes were assessed at 10 to
14 days after treatment (short-term follow-up) and at 42 to 63 days after treatment
(long-term follow-up). The investigators excluded 69 women (28%) who did not
meet inclusion after enrollment (eg, diagnosis other than pyelonephritis), and 23
women (13%) who had incomplete follow-up. Among the remaining 156 patients, 16
(22%) in the 7-day treatment group and 26 (32%) in the 14-day treatment group
had positive blood cultures.RESULTS
At early follow-up, women who received 7 days and 14 days of ciprofloxacin experi-
enced high cure rates (97% vs 95%; P for noninferiority, .004). Both groups also expe-
rienced similar rates for clinical failure/recurrent urinary tract infection (3% in 7-day
group vs 4% in 14-day group). At long-term follow-up, rates for cure (93% vs 93%)
and clinical failure (7% vs 7%) also were similar in both groups, but patients treated
for 7 days were significantly less likely to experience a mucosal yeast infection (0%
vs 6%, P 5 .04). The investigators found no significant differences in cure rates be-
tween treatment in the subgroup of patients with positive blood cultures (P 5 .62).SUMMARY
The ability to generalize from this study is limited to fluoroquinolones and to moder-
ately ill patients with uncomplicated infections. Nevertheless, this rigorous study
provides hospitalists with a convenient, short-course treatment option that can
facilitate early discharge and improve medication adherence in the post–acute
care setting.Can a dog be trained to recognize C. difficile infection?
Bomers MK, Agtmael MA, Luik H, et al. Using a dog’s superior olfactory sensi-
tivity to identify Clostridium difficile in stools and patients: proof of principle
study BMJ 2012;345:e7396.BACKGROUND/PURPOSE
C. difficile infection is a common complication of hospitalization and is becoming
more frequent, severe, and refractory to standard treatment. Rapid diagnosis of
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treatment.
STUDY DESIGN
In this proof-of-principle study the investigators trained a single beagle to smell and
recognize toxigenic strains of C. difficile. For training, C. difficile was cultured on stan-
dard media under anaerobic conditions. The dog was exposed to the cultured strains
by using sticks, fabrics, and metals that had been placed in contact with the cultures
for varying periods of time. The dog was trained by a professional dog trainer to sit or
lie down when it detected C. difficile. After training, the dog was tested with 100 stool
samples, half from patients with C. difficile infection, and half from controls. In addi-
tion, to determine the dog’s ability to identify C. difficile infection in a clinical setting,
the dog was taken to the hospital wards and to patient rooms. Using a blinded
case-control design, the investigators tested the dog on 30 patients with confirmed
C. difficile infection, and 270 control patients.
RESULTS
The dog performed well when tested on stool samples (sensitivity 100%, specificity
94%). The dog also performed well when identifying C. difficile infection in patients
in hospital rooms (sensitivity 93%, specificity 97%). The dog registered an inconclu-
sive response in only 7 of 300 patients. However, this study has several limitations.
Although the dog trainer was blinded to the status of patients when the dog was tested
on the hospital wards, there were several mechanisms that may have unblinded the
trainer and biased the results. First, the patients were presented in blocks of 10 with
1 positive patient in each block, allowing the trainer to anticipate only 1 positive in
each block. Next, many of the patients with C. difficile infection were placed in isola-
tion rooms, which may have unblinded the trainer. In addition, there may have been
other clinical cues that may have allowed the trainer to guess whether a patient had
C. difficile infection. Because of these potential biases, it is likely that the study design
resulted in an overestimation of the dog’s performance.
SUMMARY
Despite the limitations, this study is a proof of principle and suggests that C. difficile
may be detected quickly in a clinical setting, allowing the rapid initiation of infection
control measures and treatment.
